KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Astrazeneca (AZN) over the last 11 years, with Q2 2025 value amounting to -$34.1 billion.

  • Astrazeneca's Total Non-Current Liabilities rose 580.5% to -$34.1 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$34.1 billion, marking a year-over-year increase of 580.5%. This contributed to the annual value of -$35.3 billion for FY2024, which is 21237.46% down from last year.
  • Latest data reveals that Astrazeneca reported Total Non-Current Liabilities of -$34.1 billion as of Q2 2025, which was up 580.5% from -$35.3 billion recorded in Q4 2024.
  • In the past 5 years, Astrazeneca's Total Non-Current Liabilities registered a high of $43.5 billion during Q4 2021, and its lowest value of -$38.8 billion during Q2 2022.
  • Over the past 5 years, Astrazeneca's median Total Non-Current Liabilities value was -$34.1 billion (recorded in 2025), while the average stood at -$11.6 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 4124.87% in 2021, then plummeted by 21237.46% in 2024.
  • Astrazeneca's Total Non-Current Liabilities (Quarter) stood at $43.5 billion in 2021, then fell by 23.8% to $33.1 billion in 2022, then dropped by 5.19% to $31.4 billion in 2023, then plummeted by 212.37% to -$35.3 billion in 2024, then increased by 3.46% to -$34.1 billion in 2025.
  • Its Total Non-Current Liabilities stands at -$34.1 billion for Q2 2025, versus -$35.3 billion for Q4 2024 and -$36.2 billion for Q2 2024.